Montelukast Aurovitas

Montelukast, the active ingredient in Montelukast Aurovitas, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma and allergic rhinitis in adults and children as prescribed by a healthcare professional.

GNH USA supplies Montelukast Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist that addresses inflammatory airway conditions. - Asthma: improves control of chronic asthma and reduces the frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Abdominal pain: discomfort or cramping in the stomach area. - Cough: occasional irritation of the throat. - Dyspepsia: indigestion or feeling of fullness. - Nausea: sensation of needing to vomit. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic enzyme elevations: abnormal liver function tests. - Neutropenia: reduced white blood cell count. - Stevens‑Johnson syndrome: severe skin blistering. - Severe respiratory distress: unexpected worsening of breathing.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Pregnancy: safety category is unknown; use only if the potential benefit justifies the risk. - Breastfeeding: unknown excretion in milk; weigh benefits against possible infant exposure. - Pediatric use: follow age‑specific dosing recommendations provided by the prescriber. - Neuropsychiatric monitoring: observe patients for mood changes or behavioral disturbances. - Hypersensitivity: discontinue if an allergic reaction occurs. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may reduce montelukast plasma levels. - Phenobarbital: may significantly lower therapeutic effect.

Moderate Interactions (Monitor Closely): - Fluconazole: potential increase in montelukast exposure. - Erythromycin: may modestly raise drug concentrations. - Warfarin: monitor INR as montelukast could affect anticoagulation. - Oral contraceptives: possible reduction in contraceptive effectiveness.